Brookline Capital Markets Weighs in on INTS FY2029 Earnings

Posted by George Bondi on Aug 19th, 2026

Intensity Therapeutics Inc. (NASDAQ:INTS – Free Report) – Stock analysts at Brookline Capital Markets increased their FY2029 earnings estimates for Intensity Therapeutics in a research note issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now forecasts that the company will earn $7.40 per share for the year, up from their previous estimate of $7.33. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.41) per share.

Other research analysts have also recently issued reports about the stock. Benchmark reaffirmed a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Finally, HC Wainwright lifted their price objective on Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $22.25.

Check Out Our Latest Stock Report on Intensity Therapeutics

Intensity Therapeutics Stock Performance

NASDAQ INTS opened at $4.21 on Monday. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $13.72 million, a P/E ratio of -1.18 and a beta of 2.76. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The firm has a 50-day moving average price of $4.27 and a two-hundred day moving average price of $5.44.

Intensity Therapeutics (NASDAQ:INTS – Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24).

Institutional Investors Weigh In On Intensity Therapeutics

Hedge funds have recently modified their holdings of the company. Mesirow Financial Investment Management Inc. raised its position in Intensity Therapeutics by 25.5% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after purchasing an additional 51,000 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Intensity Therapeutics during the fourth quarter valued at about $26,000. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics during the fourth quarter worth about $41,000. State Street Corp grew its holdings in shares of Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares during the last quarter. Finally, Legacy Advisors LLC acquired a new position in shares of Intensity Therapeutics in the fourth quarter valued at approximately $63,000. Institutional investors and hedge funds own 3.74% of the company’s stock.

About Intensity Therapeutics

(Get Free Report)

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.